-
Innovation Ranking
NewInnovation Ranking – Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc (Acadia) discovers, develops, and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company’s marketed product Nuplazid (pimavanserin) is an FDA-approved drug for the treatment of Parkinson’s disease psychosis. It's pipeline includes pimavanserin for the treatment of various indications which include Schizophrenia, Major Depressive Disorder (MDD), dementia-related psychosis (DRP), and trofinetide for the treatment of Rett Syndrome. The company markets its product in the US. It has operational presence in Denmark, Switzerland,...
-
Product Insights
Acadia Power Station
Acadia Power Station is a thermal project located in Louisiana, United States. The project is owned by Cleco Power LLC; Entergy Louisiana LLC. The project came online in 2002. Empower your strategies with our Acadia Power Station report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Product Insights
NewNet Present Value Model: Acadia Pharmaceuticals Inc’s Trofinetide
Empower your strategies with our Net Present Value Model: Acadia Pharmaceuticals Inc's Trofinetide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Acadia Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Acadia Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Acadia Healthcare Co Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Acadia Healthcare Co Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-204 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-204 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-204 in Alzheimer's Disease Drug Details: ACP-204 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACP-204 in Psychosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-204 in Psychosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-204 in Psychosis Drug Details: ACP-204 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pimavanserin Tartrate in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pimavanserin Tartrate in Schizophrenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pimavanserin Tartrate in Schizophrenia Drug Details: Pimavanserin tartrate (Nuplazid) is a phenol...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gebasaxturev in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gebasaxturev in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gebasaxturev in Oropharyngeal Cancer Drug Details: Cavatak (Coxsackievirus A21, CVA-21) is...
-
Product Insights
Psychosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psychosis - Drugs In Development, 2023’, provides an overview of the Psychosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...